Instituto de Cancer de Londrina

Londrina 86015-520

1 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, Head and Neck Cancer

Studies at this site

• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early